Tesomet

Phase 2Small molecule

SSaniona

Tesomet is one of 41 small molecule programs targeting Prader-Willi syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prader-Willi SyndromeActive, not recruiting

Hypothalamic ObesityActive, not recruiting

Prader-Willi SyndromePhase 2

Active, not recruiting

Hypothalamic ObesityPhase 2

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Prader-Willi Syndrome

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

2 2

Topamax

WWim Janssens

Approved

1 3

Intuniv

PPromius Pharma, LLC

Approved

1 4

Growth Hormone

Pfizer

Approved

1 5

Wakix

HHarmony Biosciences Management, Inc.

Phase 3

3 6

Pabal

AACADIA Pharmaceuticals Inc.

Phase 3

2 7

Sandostatin LAR

Novartis

Phase 3

1 8

Rimonabant

Sanofi

Phase 3

1 9

Genotropin

Pfizer

Phase 3

1 10

Nutropin AQ

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prader-Willi syndrome1 trial

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

Withdrawn·SSaniona·Phase 2·NCT05198362

Hypothalamic Obesity1 trial

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

Withdrawn·SSaniona·Phase 2·NCT05147415

Unspecified1 trial

Study to Investigate the Pharmacokinetic Profile

Completed·SSaniona·Phase 1·NCT03286829·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tesomet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tesomet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tesomet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Saniona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSaniona

Tesomet

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prader-Willi syndrome1 trial

Hypothalamic Obesity1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News